All In Biotech

NDA 020404 · Mylan Pharms INC

Avita

Tretinoin · Topical · Retinoid

Last checked: Nov 19, 2026Latest source record: Jan 22, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Jan 14, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

375

82 Phase 3, 25 recruiting

FAERS reports

6,524

4,112 serious, 851 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 11, 2024.

INDICATIONS AND USAGE Tretinoin Cream, USP is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of this product in the treatment of other disorders have not been established.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 14, 1997 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • AVITA · TRETINOIN 0.025% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tretinoin" as an intervention, any sponsor and status, largest first.

All 375 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use876
  • drug ineffective727
  • pain489
  • product use in unapproved indication483
  • vomiting450
  • paraesthesia372
  • abdominal pain upper368
  • rash361
  • nausea350
  • diarrhoea347
  • maternal exposure during pregnancy338
  • headache335

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
200531
200624
200739
2008114
200972
201078
201189
2012153
2013100
2014147
2015223
2016342
2017343
2018460
2019350
2020374
2021426
2022510
2023568
2024674
2025809
2026561

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 425 on PubMed

Sponsor: Mylan Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.